Literature DB >> 18027237

Preservation of influenza virosome structure and function during freeze-drying and storage.

Jan Wilschut1, Jørgen de Jonge, Anke Huckriede, Jean-Pierre Amorij, Wouter L J Hinrichs, Henderik W Frijlink.   

Abstract

Virosomes derived from influenza virus are reconstituted viral envelopes, which retain the receptor-binding and cell entry properties of the native virus, but lack the viral genetic material. These virosomes are of interest because of their potential use as vaccines or cellular delivery systems. However, in aqueous dispersion influenza virosomes have a relatively poor stability. Although freeze-drying of the virosomes could improve their stability, a lyoprotectant is required to preserve the structure and function of the virosomes during the lyophilization process as well as during subsequent storage of the dry powder formulation. In this study, inulin, a medium-chain oligosaccharide, was identified as an effective stabilizer of influenza virosomes. When inulin was added to an aqueous virosomal dispersion, the vesicular structure of the virosomes, with spike proteins protruding from the virosomal surface, as well as their membrane fusion activity were completely preserved during freeze-drying. When the freeze-drying process was performed from dispersions lacking a lyoprotectant, both structure and fusogenic properties of the virosomes were lost. Moreover, it was shown that the immunogenicity of inulin-stabilized virosomes was preserved. For example, dry powder formulations of virosomes retained HA potency for at least 12 weeks at 20 degrees C. Virosomes with encapsulated pDNA encoding for the eGFP reporter gene were also found to be stabilized by inulin. The fusion capacity and the transfection efficacy (determined in BHK-21 cells) could be preserved for 12 weeks during storage at 4 degrees C. It is concluded that freeze-drying in the presence of inulin as a lyoprotectant completely preserves the structure and function of influenza virosomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18027237     DOI: 10.1080/08982100701536883

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  5 in total

1.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

2.  Reconstruction of H3N2 influenza virus based virosome in-vitro.

Authors:  Asghar Abdoli; Hoorieh Soleimanjahi; Masoumeh Tavassoti Kheiri; Abbas Jamali; Hesam Sohani; Mohsen Abdoli; Hamid Reza Rahmatollahi
Journal:  Iran J Microbiol       Date:  2013-06

Review 3.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

5.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.